1-5 of 5
Neil R. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

David W. Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N. Foltz, Brandon C. Clavette, Kathy Manchulenko, Cath Eberlein, Jane Kendrew, Philip Petteruti, Song Cho, Melissa Damschroder, Li Peng, Dawn Baker, Neil R. Smith, Hazel M. Weir, David C. Blakey, Vahe Bedian, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1650–1660.
https://doi.org/10.1158/1535-7163.MCT-11-1027
Published: 08 August 2012
View article titled, MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <em>In Vivo</em>
Open the PDF for MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

Denis G. Alferez, Helen Brown, Jonathan R. Dry, Sarah Runswick, Neil James, Gael McWalter, Jessica Whiteley, Mitch Revill, Garry Beran, Matthew Farren, Neil R. Smith, Phillip Hedge, Simon Barry, Stephen R. Wedge, Robert W. Wilkinson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A13.
https://doi.org/10.1158/1535-7163.TARG-11-A13
Published: 12 November 2011
View article titled, Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.
Journal Articles

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R. Smith, Hazel M. Weir, Stephen R. Wedge, David C. Blakey, Ian Foltz, Joe Zhou, Jaspal S. Kang, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 770–783.
https://doi.org/10.1158/1535-7163.MCT-10-0876
Published: 08 May 2011
View article titled, An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding
Open the PDF for An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding in another window
Journal Articles

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice

Denis Alferez, Robert W. Wilkinson, Jim Watkins, Richard Poulsom, Nikki Mandir, Stephen R. Wedge, Ian T. Pyrah, Neil R. Smith, Lynsay Jackson, Anderson J. Ryan, Robert A. Goodlad
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 590–598.
https://doi.org/10.1158/1535-7163.MCT-07-0433
Published: 17 March 2008
View article titled, Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in <em>Apc</em><sup>Min/+</sup> mice
Open the PDF for Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in <em>Apc</em><sup>Min/+</sup> mice in another window
Journal Articles

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

Neil R. Smith, Neil H. James, Ian Oakley, Anna Wainwright, Clive Copley, Jane Kendrew, Lynsey M. Womersley, Juliane M. Jürgensmeier, Stephen R. Wedge, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (8): 2198–2208.
https://doi.org/10.1158/1535-7163.MCT-07-0142
Published: 15 August 2007
View article titled, Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts
Open the PDF for Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts in another window